المؤلفون: Andrew M. Will, Bryce A. Kerlin, Michael Williams, M. Sandberg Lundblad, Diane J. Nugent, C. W. Tornøe, Manuel Carcao, B. Brand-Staufer

المصدر: Haemophilia. 21:380-385

مصطلحات موضوعية: Adult, Male, Adolescent, Population, Physiology, Pharmacology, law.invention, Young Adult, Pharmacokinetics, Age groups, Risk Factors, law, Humans, Medicine, Dosing, Child, education, Genetics (clinical), Volume of distribution, education.field_of_study, Factor XIII, business.industry, Infant, Hematology, General Medicine, Factor XIII Deficiency, Recombinant Proteins, Protein Subunits, Treatment Outcome, Child, Preschool, Recombinant DNA, Female, Geometric mean, Factor XIIIa, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b665ce92e0f467e82b6c7aa2c5fbbd18
https://doi.org/10.1111/hae.12616

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Gottlieb AB; Department of Dermatology, Tufts Medical Center, Boston, MA, United States of America; Department of Dermatology, Tufts University School of Medicine, Boston, MA, United States of America., Krueger JG; The Rockefeller University, New York, NY, United States of America., Sandberg Lundblad M; Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark., Göthberg M; Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark., Skolnick BE; Medical-Science, Inflammation, Novo Nordisk Inc., Princeton, NJ, United States of America.

المصدر: PloS one [PLoS One] 2015 Aug 07; Vol. 10 (8), pp. e0134703. Date of Electronic Publication: 2015 Aug 07 (Print Publication: 2015).

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Antibodies, Neutralizing/*therapeutic use , Interleukins/*immunology , Psoriasis/*drug therapy, Adult ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing/adverse effects ; Antibodies, Neutralizing/pharmacology ; Broadly Neutralizing Antibodies ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Psoriasis/pathology ; Recombinant Proteins/adverse effects ; Recombinant Proteins/pharmacokinetics ; Recombinant Proteins/pharmacology ; Recombinant Proteins/therapeutic use ; Treatment Outcome ; Young Adult